Condition: Non-Hodgkin Lymphoma · Follicular Lymphoma · DLBCL · Sponsor: IGM Biosciences, Inc.
This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage, a combination stage, and a randomized dose-expansion stage where subjects will be enrolled into indication-specific expansion cohorts. imvotamab will be administered intravenously (IV). Additional CD20-positive NHL histologies (e.g. MZL and MCL), may be allowed with Medical Monitor approval during the Dose-Escalation Phase of the study.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Norton Cancer Institute | Louisville, Kentucky, United States | — |
| Dana Farber Cancer Institute (DFCI) | Boston, Massachusetts, United States | — |
| NYU | New York, New York, United States | — |
| MSKCC | New York, New York, United States | — |
| Tennessee Oncology | Nashville, Tennessee, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Fred Hutch | Seattle, Washington, United States | — |
| Monash Health | Clayton, Victoria, Australia | — |
| St. Vincent's Hospital Melbourne | Fitzroy, Victoria, Australia | — |
| Linear Clinical Resaerch | Nedlands, Western Australia, Australia | — |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04082936